Pregabalin Capsule
Product Images NDC 80425-0308

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0308). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

A formula showing the calculation for creatinine clearance (CLcr) based on age, weight, and serum creatinine, with an adjustment factor of 0.85 for female patients. This text panel likely relates to clinical dosing considerations for the medication Pregabalin 200 mg oral capsules.*

FDA Label Image

Fig 1 (Fig 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 200 mg, 100 mg, and 25 mg three times a day compared to placebo. The graph depicts higher improvement for Pregabalin doses, with 200 mg showing the greatest effect.*

FDA Label Image

Fig 10 (Fig 10)

A survival curve chart showing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus placebo. The vertical axis ranges from 0% to 100%, and the horizontal axis represents days. Pregabalin is represented by a solid line, placebo by a dashed line, with the Pregabalin line consistently above placebo throughout the timeline.*

FDA Label Image

Fig 11 (Fig 11)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo groups. The x-axis represents percent improvement from baseline to week 12 BOCF, ranging from greater than 0 to 100 percent. The y-axis represents the percent of subjects improved, from 0 to 100 percent. The solid line shows data for Pregabalin, and the dotted line shows data for Placebo, with Pregabalin consistently showing higher improvement percentages.*

FDA Label Image

Fig 12 (Fig 12)

A line graph comparing the percentage of subjects improved from baseline to week 16 BOCF between Pregabalin and placebo groups. The x-axis represents percent improvement from 0 to 100%, and the y-axis shows the percent of subjects improved, with Pregabalin depicted by a solid line and placebo by a dashed line, indicating higher improvement rates with Pregabalin.*

FDA Label Image

Fig 2 (Fig 2)

A line chart depicting the percent of patients improved versus percent improvement in pain from baseline. It compares two groups: patients taking pregabalin 100 mg three times a day and a placebo group, showing greater pain improvement in the pregabalin group.*

FDA Label Image

Fig 3 (Fig 3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared to a placebo. The graph illustrates varying efficacy levels at different pain improvement percentages.*

FDA Label Image

Fig 4 (Fig 4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph depicts higher percentages of improvement with Pregabalin 200 mg compared to Pregabalin 100 mg and placebo across the pain improvement scale.*

FDA Label Image

Fig 5 (Fig 5)

A line chart showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The chart displays how patient improvement varies with increasing percentage of pain relief.*

FDA Label Image

Fig 6 (Fig 6)

A bar chart comparing responder rates (%) across different dosages of pregabalin and placebo in two studies, Study E1 and Study E3. The x-axis shows dosages and placebo groups with respective sample sizes, while the y-axis shows responder rates from 0% to 60%. Statistically significant increases versus placebo are noted for various pregabalin dosages.*

FDA Label Image

Fig 7 (Fig 7)

A line graph depicting seizure reduction as median percent change from baseline versus dose (mg/day) of Pregabalin. The graph includes data points from multiple studies (E1 BD, E2 TID, E3 BD, E3 TID) with significant p-values marked for each data set. The x-axis represents dose in mg/day, and the y-axis represents seizure reduction percentage.*

FDA Label Image

Fig 9 (Fig 9)

A line graph depicting the percent of patients improved versus the percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 800 mg daily doses, compared to placebo. The graph shows a declining trend in patient improvement percentages as pain improvement increases from 0 to 100%.*

FDA Label Image

Label 1 (Pregabalin 200mg 80425 0308 01)

Label for Pregabalin 200 mg capsule from Advanced Rx Pharmacy of Tennessee, LLC. The label includes the product NDC 80425-0308, compares to Lyrica, and shows a package quantity of 30 capsules. Storage instructions specify 20-25°C (68°-77°F). Manufacturer listed as Sciegen Pharmac.*

FDA Label Image

Label 2 (Pregabalin 200mg 80425 0308 02)

Pregabalin 200 mg capsule packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions to keep at 20°-25°C (68°-77°F) and a caution for patients to report adverse effects to their doctor. It shows the quantity as 60 capsules and compares to Lyrica with NDC information. Expiration date area is indicated but obscured.*

FDA Label Image

Label 3 (Pregabalin 200mg 80425 0308 03)

Pregabalin 200 mg capsule label from Advanced Rx Pharmacy of Tennessee, LLC, Nashville. The label includes storage instructions (20°-25°C, 68°-77°F), comparison to Lyrica with associated NDC codes, and expiration in August 2024. The label features a barcode and lot number placeholder.*

FDA Label Image

Structure (Structure)

Chemical structure of pregabalin, showing its molecular framework including functional groups such as an amino group (NH2) and a carboxyl group (CO2H). This structural diagram represents the active ingredient pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.